PAI-1 Levels & Metabolic Liver Disease: Review & Meta-Analysis
Petäjä EM, Yki-Järvinen H. Definitions of normal liver fat and the association of insulin sensitivity with acquired and genetic NAFLD-A systematic review. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17050633.
Google Scholar
Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49(2):197–211. https://doi.org/10.1080/03602532.2017.1293683.
Google Scholar
Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1): 101133. https://doi.org/10.1016/j.aohep.2023.101133.
Google Scholar
Eslam M, George J. MASLD: now is the time to capitalize on the momentum. J Hepatol. 2021;74(5):1262–3. https://doi.org/10.1016/j.jhep.2021.02.002.
Google Scholar
Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9. https://doi.org/10.1016/j.jhep.2020.03.039.
Google Scholar
Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med. Sep 2005;22(9):1129–33. https://doi.org/10.1111/j.1464-5491.2005.01748.x.
Eslam M, Sanyal AJ, George J. MASLD: A Consensus-Driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology May. 2020;158(7):1999–e20141. https://doi.org/10.1053/j.gastro.2019.11.312.
Google Scholar
Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–82. https://doi.org/10.1002/hep.30251.
Google Scholar
Masoodi M, Gastaldelli A, Hyötyläinen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests. Nat Rev Gastroenterol Hepatol. 2021;18(12):835–56. https://doi.org/10.1038/s41575-021-00502-9.
Google Scholar
Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with Long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology Aug. 2015;149(2):389–e9710. https://doi.org/10.1053/j.gastro.2015.04.043.
Google Scholar
Kruithof EK. Plasminogen activator inhibitors–a review. Enzyme. 1988;40(2–3):113–21. https://doi.org/10.1159/000469153.
Google Scholar
Levine JA, Oleaga C, Eren M, et al. Role of PAI-1 in hepatic steatosis and dyslipidemia. Sci Rep. 2021;11(1): 430. https://doi.org/10.1038/s41598-020-79948-x.
Google Scholar
Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol. 2006;26(10):2200–7. https://doi.org/10.1161/01.Atv.0000242905.41404.68.
Google Scholar
Kaji H. Adipose Tissue-Derived plasminogen activator Inhibitor-1 function and regulation. Compr Physiol Sep. 2016;15(4):1873–96. https://doi.org/10.1002/cphy.c160004.
Google Scholar
Jin R, Krasinskas A, Le NA, Konomi JV, Holzberg J, Romero R, et al. Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease. Pediatr Obes. 2018;13(1):23–9. https://doi.org/10.1111/ijpo.12183.
Google Scholar
Higgins JPT, Thomas J, Chandler J, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane. 2024. www.training.cochrane.org/handbook. Accessed 24 August 2024.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. https://doi.org/10.1186/s13643-021-01626-4.
Google Scholar
Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MASLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–9. https://doi.org/10.1111/liv.14548.
Google Scholar
Stang A. Critical evaluation of the Newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.
Google Scholar
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. https://doi.org/10.1186/1471-2288-14-135.
Google Scholar
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805. https://doi.org/10.1177/0962280216669183.
Google Scholar
Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(Pt 1):97–128. https://doi.org/10.1348/000711007×255327.
Google Scholar
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.
Google Scholar
Younossi ZM. Non-alcoholic fatty liver disease – a global public health perspective. J Hepatol. 2019;70(3):531–44. https://doi.org/10.1016/j.jhep.2018.10.033.
Google Scholar
Abdel-Razik A, Mousa N, Shabana W, Yassen AH, Abdelsalam M, Wahba MM, et al. De Novo portal vein thrombosis in Non-Cirrhotic Non-Alcoholic fatty liver disease: A 9-Year prospective cohort study. Front Med (Lausanne). 2021;8:650818. https://doi.org/10.3389/fmed.2021.650818.
Google Scholar
Alvares-da-Silva MR, by Oliveira CP, Stefano JT, HV Barber, Barber D, Soriano FG, et al. Pro-Aetherosclerotic Markers and Cardiovascular Risk Factors One Year After Liver Transplantation. World J Gastroenterol. 2014; 20 (26): 8667–73. https://doi.org/10.3748/wjg.v20.i26.8667.
Google Scholar
Bai XP, Yang YL, Gao M, Li X, Zhao BZ. The influence of serum triglycerides on plasminogen activator inhibitor-1 and adiponectin in patients with nonalcoholic fatty liver disease. Chin J Gastroenterol Hepatol. 2014;23(04):435–7.
Google Scholar
Bilgir O, Bilgir F, Bozkaya G, Calan M. Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease. Blood Coagul Fibrinolysis. 2014;25(2):151–5. https://doi.org/10.1097/mbc.0000000000000009.
Google Scholar
Cao Y, Li L. Relationship of non-alcoholic steatohepatitis with arterial endothelial function and atherosclerosis. Chin J Hepatol. 2014;22(3):205–8. https://doi.org/10.3760/cma.j.issn.1007-3418.2014.03.012.
Google Scholar
Chang ML, Hsu CM, Tseng JH, Tsou YK, Chen SC, Shiau SS, et al. Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders. J Gastroenterol Hepatol. 2015;30(2):329–36. https://doi.org/10.1111/jgh.12705.
Google Scholar
Chen HY, Zhu SW, Wu WJ, Bu RF. Effect of serum triglyceride on PAI-1 and APN levels in patients with nonalcoholic fatty liver disease. Mod Diagn Treat. 2015;26(15):3375–7.
Google Scholar
Deng YQ, Fan XF, Li JP. Fibrinolytic status in nonalcoholic fatty liver patients with different glucose tolerance levels. Zhejiang J Integr Traditional Chin Western Med. 2005(09):547–8.
Deng YQ, Fan XF, Li YD. Relationship between phlegm-stasis syndrome and fibrinolytic status in patients with non-alcoholic fatty liver. Chin J Integr Tradit Western Med. 2005;25(1):22–4.
Google Scholar
Fang LM, Shen NY, Ma QH, Chen KL, Liu D. Changes and significance of plasminogen activator inhibitor-1 level in nonalcoholic fatty liver disease. Chin J Practical Med. 2010;37(13):74–5. https://doi.org/10.3760/cma.j.issn.1674-4756.2010.13.036.
Google Scholar
Jiang X, Sun M. Changes and clinical significance of serum PAI-1 in nonalcoholic fatty liver disease. Chin J Lab Diagn. 2020;24(06):953–5.
Google Scholar
Kargili A, Cipil H, Karakurt F, Kasapoglu B, Koca C, Aydin M, et al. Hemostatic alterations in fatty liver disease. Blood Coagul Fibrinolysis. 2010;21(4):325–7. https://doi.org/10.1097/mbc.0b013e328337b3f8.
Google Scholar
Li Y, Liu L, Wang B, Wang J, Chen D. Simple steatosis is a more relevant source of serum inflammatory markers than omental adipose tissue. Clin Res Hepatol Gastroenterol. 2014;38(1):46–54. https://doi.org/10.1016/j.clinre.2013.08.006.
Google Scholar
Nier A, Huber Y, Labenz C, Michel M, Bergheim I, Schattenberg JM. Adipokines and endotoxemia correlate with hepatic steatosis in non-alcoholic fatty liver disease (NAFLD). Nutrients. 2020. https://doi.org/10.3390/nu12030699.
Google Scholar
Targhs G, Bertolini L, Rodella S, Lime G, Franking M, Zopupni G, et al. NASH preaching inflammatory biomarkers of visceral biomarks made in less. Obesity. 2008;16(6):1394–9. https://doi.org/10.1038/oby.2008.64.
Google Scholar
Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138(8):1452–5. https://doi.org/10.1093/jn/138.8.1452.
Google Scholar
Tian S, Liu HL, Zhong XQ. Diagnostic significance of serum plasminogen activator inhibitor-1 level for nonalcoholic fatty liver disease. Mod J Integr Traditional Chin Western Med. 2020;29(06):585–8.
Google Scholar
Volynets V, Küper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2012;57(7):1932–41. https://doi.org/10.1007/s10620-012-2112-9.
Google Scholar
Yang YQ, Zhang Y, Kou SJ, Dong L. Study on the relationship between fatty liver severity and oxidative stress,saa, CRP and cerebral arteriosclerosis in fatty liver patients. Chin J Integr Med. 2022;32(6):520–4. https://doi.org/10.3969/j.issn.1005-0264.2022.06.012.
Google Scholar
Xu L, Ding XY, Weng YS, Miu M, Yuan JY. Changes in the coagulation fibrinolysis system in nonalcoholic fatty liver disease. Chin J Rural Med Pharm. 2011;18(11):59–60. https://doi.org/10.19542/j.cnki.1006-5180.2011.11.044.
Google Scholar
Wang C, Yan J, Zhang S, Xie Y, Nie Y, Chen Z, et al. Screening new blood indicators for Non-alcoholic fatty liver disease (NAFLD) diagnosis of Chinese based on machine learning. Front Med (Lausanne). 2022;9:771219. PubMed PMID: 35755070; PubMed Central PMCID: PMCPMC9218755.
Google Scholar
Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, et al. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis. J Endocrinol Invest. 2007;30(10):810–9. https://doi.org/10.1007/bf03349221.
Google Scholar
Zhu JZ, Zhu HT, Tuesday, Li CX, Fang Zo, Zhao, Zhao, and DJ, eli al. Serum periost is a biomarker for non-alcoholic diversity, a discipline: a disclosure. Endomined. 2016;51(1):91–100. https://doi.org/10.1007/s12020-015-0735-2.
Google Scholar
Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab. 2021;23(5):1069–83. https://doi.org/10.1007/s12020-015-0735-2.
Google Scholar
Fassio E, alvarez e, domínguez n, landeira g, jongo C. Natural History of Nonalcoholic Steatohepatitis: A Longital Study of Repeat Liver Biopses. Hepatology. 2004;40(4):820–6 https://doi.org/10.1002/hep.20410.
Google Scholar
Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinology, Diabetes & Metabolism. 2020;3(4): e00112. https://doi.org/10.1002/edm2.112.
Google Scholar
Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60(1):167–74. https://doi.org/10.1016/j.jhep.2013.07.042.
Google Scholar
Hu J, Ke Y, Wu F, Liu S, Ji C, Zhu X, et al. Circulating Irisin levels in patients with nonalcoholic fatty liver disease: A systematic review and Meta-Analysis. Gastroenterol Res Pract. 2020;2020:8818191. https://doi.org/10.1155/2020/8818191.
Google Scholar
Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia. 2016;59(1):30–43. https://doi.org/10.1007/s00125-015-3769-3.
Google Scholar
Agren A, Jörneskog G, Elgue G, Henriksson P, Wallen H, Wiman B. Increased incorporation of antiplasmin into the fibrin network in patients with type 1 diabetes. Diabetes Care. 2014;37(7):2007–14. https://doi.org/10.2337/dc13-1776.
Google Scholar
Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA. 2000;97(22):12222–6. https://doi.org/10.1073/pnas.97.22.12222.
Google Scholar
Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE. Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells. J Biol Chem. 1998;273(14):8225–31.
Google Scholar
Beier JI, Arteel GE. Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism. Exp Biol Med (Maywood). 2012;237(1):1–9. https://doi.org/10.1074/jbc.273.14.8225.
Google Scholar
Beier JI, Luyendyk JP, Guo L, von Montfort C, Staunton DE, Arteel GE. Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharide-induced liver injury caused by ethanol in mice. Hepatology. 2009;49(5):1545–53. https://doi.org/10.1002/hep.22847.
Google Scholar
Alsharoh H, Ismaiel A, Leucuta DC, Popa SL, Dumitrascu DL. Plasminogen activator inhibitor-1 levels in non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Gastrointestin Liver Dis. 2022;31(2):206–14. https://doi.org/10.15403/jgld-4091.
Google Scholar
Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, et al. Circulating interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis. Int J Cardiol. 2018;259:198–204. https://doi.org/10.1016/j.ijcard.2018.01.046.
Google Scholar
Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017;65(1):65–77. https://doi.org/10.1002/hep.28776.
Google Scholar
Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis. 2010;209(2):585–91. https://doi.org/10.1016/j.atherosclerosis.2009.10.011.
Google Scholar
Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, et al. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int. 2020;40(5):1111–20. https://doi.org/10.1111/liv.14417.
Google Scholar
Pan JJ, Fallon MB. Gender and Racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014;6(5):274–83. https://doi.org/10.4254/wjh.v6.i5.274.
Google Scholar
Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, PENNACCHIO la, et al. genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–5. https://doi.org/10.1038/ng.257.
Google Scholar
Zoratti R. A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur J Epidemiol. 1998;14(1):9–21. https://doi.org/10.1023/a:1007492202045.
Google Scholar
Lomonaco R, Ortiz-Lopez C, Orsak B, Finch J, Webb A, Bril F, et al. Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis. Hepatology. 2011;54(3):837–45. https://doi.org/10.1002/hep.24483.
Google Scholar
Souza M, et al. Representation of sex, race and ethnicity in MASH randomised controlled trials: A systematic review and Meta-Analysis. Liver Int. 2025;45(4):e70029. https://doi.org/10.1111/liv.70029.
Google Scholar
Crudele L, et al. Fatty liver index (FLI) is the best score to predict MASLD with 50% lower cut-off value in women than in men. Biol Sex Differ. 2024;15(1):43. https://doi.org/10.1186/s13293-024-00617-z.
Google Scholar
Lonardo A, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70(4):1457–69. https://doi.org/10.1002/hep.30626.
Google Scholar
Tague BW. Germ-line transformation of Arabidopsis lasiocarpa. Transgenic Res. 2001;10(3):259–67. https://doi.org/10.1023/a:1016633617908.
Google Scholar
Holzberg JR, Jin R, Le NA, Ziegler TR, Brunt EM, McClain CJ, et al. Plasminogen activator Inhibitor-1 predicts quantity of hepatic steatosis independent of insulin resistance and body weight. J Pediatr Gastroenterol Nutr. 2016;62(6):819–23. https://doi.org/10.1097/mpg.0000000000001096.
Google Scholar